Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation

Award Number: R01AI201425
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/04/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation - Project Summary ~2.4 million people in the United States have Inflammatory Bowel Disease (IBD), a chronic immune-mediated condition encompassing Crohn’s disease and ulcerative colitis. A major limitation of current IBD therapies is systemic toxicity due to on- and off-target effects. Anti-TNF therapies, though widely used, fail in ~40% of patients and can cause serious adverse events, such as pulmonary infections, autoimmune dermatological disorders, and malignancy. Recombinant IL-10, despite strong anti-inflammatory properties and success in murine studies showed limited efficacy in clinical trials for a number of reasons, including inadequate intestinal bioavailability. As such, there are significant efforts to durably target therapeutic agents directly to the inflamed intestine. A potential breakthrough for localized biologic delivery in the gut is use of engineered long-lived plasma cells, terminally differentiated B cells that reside in specific tissue niches including the intestinal lamina propria. These cells secrete antibodies for extended periods, making them an ideal platform for sustained therapeutic protein delivery. B cell activation and differentiation are regulated by B cell receptor engagement, and interactions with cognate helper T cells that provide cytokine signals to support plasma cell differentiation. Our preliminary data show that B cells engineered to express BCRs reactive to gut-localized microbial antigens are preferentially retained in gut tissues, and we hypothesize that this feature could be leveraged to produce gut-resident plasma cells capable of sustained biologic production. Our long term goal is to develop a B cell-based immunotherapy platform for treatment of IBD and related immune-mediated diseases. The primary objective in this application is to investigate the mechanisms regulating integration of engineered B cells into the host immune response, their impact on local tissue homeostasis and inflammation, and their persistence as therapeutic plasma cells. Our rationale for the proposed work is that uncovering these mechanisms has the potential to be quickly translated into therapies for IBDs. Based on strong preliminary data, we will conduct three specific aims: (1) Engineering B cells for small and large intestine targeting, and (2) Therapeutic delivery of immunomodulators for treatment of IBD. Our approach is innovative in its use of BCR specificity to direct therapeutic B cells to disease-relevant tissues, and its integration of cellular engineering, immunology and translational modeling. The proposed work is significant because it will establish new insights into the interaction and communication between commensal microbes and immune cells in the gut environment and identify potential targets for therapeutic intervention in conditions of chronic intestinal inflammation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $911,271 )
2026	2026	SEATTLE CHILDREN'S HOSPITAL	4800 SAND POINT WAY NE	SEATTLE	WA	98105	KING	USA	Allergy and Infectious Diseases Research	000	1	8/4/2026	NEW	$911,271
														Subtotal = $911,271

Grand Total All Awards = $911,271

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation

Award Number: R01AI201425

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/04/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer